Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX302 in Locally Recurrent Prostate Cancer
NCT00686088Phase 2Completed
- Sponsor
- Sophiris Bio Inc.
- Start
- Feb 2008
- Primary completion
- Sep 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topsalysin in prostate cancer (PCa), sponsored by Sophiris Bio Inc. Primary endpoints: PSA levels at Day 180, PSA doubling time at Day 180 and 2 more. Started Feb 2008; status: completed.
02
Drugs
topsalysin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00686088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686088.